Bone Marrow & Stem Cell Transplant

A trial found that off-the-shelf TRX103 Tr1 cells were safe to use after a mismatched donor stem cell transplant, showing engraftment, dose-dependent expansion, and persistence.

A phase 2 trial of acalabrutinib led to favorable response rates and tolerability in steroid-refractory chronic GVHD.

A trial of ustekinumab as graft-vs-host disease (GVHD) prophylaxis after hematopoietic cell transplant did not meet its primary end point but showed more favorable outcomes in patients who had myeloablative conditioning.

Higher doses of anti–T-lymphocyte globulin significantly reduce chronic graft-vs-host disease in matched sibling stem cell transplants, enhancing patient outcomes.

Leyla O. Shune, MD, discusses results from an interim safety analysis of a randomized phase 2 study exploring axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease.

Leyla O. Shune, MD, discusses an expanded access program in the United States that administered axatilimab to patients with chronic graft-versus-host disease. Specifically, she highlights the tolerability of axatilimab in the real-world setting.

Leyla O. Shune, MD, describes the available treatment options for patients with chronic graft-versus-host disease who are steroid refractory/dependent. She also discusses treatment approaches and results with these agents in clinical trials and in real-world settings.

During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease.

Addressing Treatment Challenges in Chronic Graft-Versus-Host Disease

Orca-T immunotherapy shows promising results in improving survival and reducing complications in patients with hematologic malignancies compared to traditional treatments.

New research reveals mismatched unrelated donors significantly improve transplant outcomes, expanding options for diverse patients in need of life-saving procedures.

MaaT013 shows promising efficacy and safety in treating refractory GI-aGVHD, offering hope for improved survival in patients.

New findings reveal the feasibility and safety of transitioning axatilimab dosing for chronic graft-vs-host disease, showing promising response rates.

The ACCESS study reveals that posttransplant cyclophosphamide improves survival rates for patients with mismatched unrelated donor transplants, expanding donor options.

Heather Stefanski, MD, PhD, discusses the unmet needs for patients undergoing bone marrow and stem cell transplants.

During a live event, Hannah Choe, MD, discussed options for steroid-resistant cGVHD based on organ involvement, efficacy, and safety profiles.

Research reveals matched unrelated donor transplants significantly enhance survival rates in leukemia patients compared with haploidentical transplants, despite donor availability.

New response criteria for acute GVHD enhance prediction of nonrelapse mortality, potentially transforming clinical trial designs and treatment evaluations.

During a live event, Hannah Choe, MD, and event participants discuss steroid-dependent chronic GVHD, favoring adding therapy over increasing steroids.

New research highlights narsoplimab's potential to significantly reduce mortality in high-risk patients with thrombotic microangiopathy after stem cell transplants.

New research reveals that sustained MRD negativity after ASCT allows safe discontinuation of lenalidomide maintenance in multiple myeloma patients.

A recent study reveals that alternative donors for hematopoietic cell transplants yield similar success rates as fully matched donors, enhancing patient outcomes.

A groundbreaking study reveals the potential of alternative donors in bone marrow transplantation, paving the way for improved patient outcomes and innovative practices.

Innovative research transforms bone marrow transplantation, enhancing outcomes with mismatched and haploidentical donors, expanding access to life-saving treatments.